Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for MRNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 588.00M
March 31, 2026 590.00M
December 31, 2025 708.00M
September 30, 2025 749.00M
June 30, 2025 643.00M
March 31, 2025 817.00M
December 31, 2024 1.062B
September 30, 2024 1.085B
June 30, 2024 1.18B
March 31, 2024 1.027B
December 31, 2023 1.204B
September 30, 2023 911.00M
June 30, 2023 1.058B
March 31, 2023 1.053B
December 31, 2022 1.131B
September 30, 2022 707.00M
June 30, 2022 634.00M
March 31, 2022 475.00M
Date Value
December 31, 2021 570.00M
September 30, 2021 451.00M
June 30, 2021 352.00M
March 31, 2021 386.00M
December 31, 2020 751.15M
September 30, 2020 335.99M
June 30, 2020 144.26M
March 31, 2020 107.69M
December 31, 2019 109.82M
September 30, 2019 112.34M
June 30, 2019 120.80M
March 31, 2019 123.10M
December 31, 2018 150.43M
September 30, 2018 109.05M
June 30, 2018 104.48M
March 31, 2018 90.12M
December 31, 2017 117.83M
September 30, 2017 93.61M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Sarepta Therapeutics, Inc. 91.26M
BioNTech SE 514.38M
Kailera Therapeutics, Inc. 101.06M
Twist Bioscience Corp. 18.02M
Revolution Medicines, Inc. 392.47M